These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19775170)

  • 1. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.
    Ramakrishnan M; Kandimalla KK; Wengenack TM; Howell KG; Poduslo JF
    Biochemistry; 2009 Nov; 48(43):10405-15. PubMed ID: 19775170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8.
    Baghallab I; Reyes-Ruiz JM; Abulnaja K; Huwait E; Glabe C
    J Alzheimers Dis; 2018; 66(3):1235-1244. PubMed ID: 30412489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonance.
    Crisostomo AC; Dang L; Digambaranath JL; Klaver AC; Loeffler DA; Payne JJ; Smith LM; Yokom AL; Finke JM
    Anal Biochem; 2015 Jul; 481():43-54. PubMed ID: 25921794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
    Wang J; Hara H; Makifuchi T; Tabira T
    J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
    Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
    J Clin Invest; 2006 Jan; 116(1):193-201. PubMed ID: 16341263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting.
    Plissonneau M; Pansieri J; Heinrich-Balard L; Morfin JF; Stransky-Heilkron N; Rivory P; Mowat P; Dumoulin M; Cohen R; Allémann É; Tόth É; Saraiva MJ; Louis C; Tillement O; Forge V; Lux F; Marquette C
    J Nanobiotechnology; 2016 Jul; 14(1):60. PubMed ID: 27455834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
    Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
    J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits.
    Kowa H; Sakakura T; Matsuura Y; Wakabayashi T; Mann DM; Duff K; Tsuji S; Hashimoto T; Iwatsubo T
    Am J Pathol; 2004 Jul; 165(1):273-81. PubMed ID: 15215182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β3-42 (pE3-Aβ).
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Wisniewski T; Miller DL
    J Alzheimers Dis; 2018; 62(4):1635-1649. PubMed ID: 29504532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
    Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
    Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
    Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
    Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
    Terai K; Iwai A; Kawabata S; Tasaki Y; Watanabe T; Miyata K; Yamaguchi T
    Neuroscience; 2001; 104(2):299-310. PubMed ID: 11377835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.
    Ramakrishnan M; Wengenack TM; Kandimalla KK; Curran GL; Gilles EJ; Ramirez-Alvarado M; Lin J; Garwood M; Jack CR; Poduslo JF
    Pharm Res; 2008 Aug; 25(8):1861-72. PubMed ID: 18443900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for passive immunotherapy of Alzheimer's disease.
    Gardberg AS; Dice LT; Ou S; Rich RL; Helmbrecht E; Ko J; Wetzel R; Myszka DG; Patterson PH; Dealwis C
    Proc Natl Acad Sci U S A; 2007 Oct; 104(40):15659-64. PubMed ID: 17895381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation.
    Ștefănescu R; Lupu L; Manea M; Iacob RE; Przybylski M
    J Pept Sci; 2018 Jan; 24(1):. PubMed ID: 29322650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide.
    Verwey NA; Hoozemans JJ; Korth C; van Royen MR; Prikulis I; Wouters D; Twaalfhoven HA; van Haastert ES; Schenk D; Scheltens P; Rozemuller AJ; Blankenstein MA; Veerhuis R
    Amyloid; 2013 Sep; 20(3):179-87. PubMed ID: 23829200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.
    Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH
    PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.